Artelo Biosciences (ARTL) Price & Analysis

Compare

545 Followers

ARTL Stock Chart & Stats

$1.24

-$0.05(-4.59%)

At close: Jan 08 4:00 PM EST

$1.24

-$0.05(-4.59%)

Day’s Range― - ―

52-Week Range$1.05 - $28.60

Previous CloseN/A

Volume8.82K

Average Volume (3M)89.20K

Market Cap

$2.49M

Enterprise Value$2.57M

Total Cash (Recent Filing)$600.00K

Total Debt (Recent Filing)$693.00K

Price to Earnings (P/E)―

Beta0.78

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding2,124,772

10 Day Avg. Volume70,584

30 Day Avg. Volume89,202

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.99

Price to Sales (P/S)0.00

P/FCF Ratio-0.15

Enterprise Value/Market Cap1.03

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.21

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical MilestonesArtelo's pipeline candidates are slated to reach important clinical milestones, which are underappreciated.

Investigational DrugART27.13 is emerging as a high-value investigational drug, as no therapies have proven to be safe treatments and approved for cancer-related cachexia.

Bears Say

Investment RisksInvestment thesis risks include failure of clinical trials to prove efficacy and potential need to raise additional funds.

Artelo Biosciences News

Artelo Biosciences announces 3-for-1 reverse stock split

Artelo Biosciences (ARTL) announced that on February 27, 2026, Artelo’s Board of Directors approved a 3-for-1 reverse stock...

1d ago

ARTL

Artelo Biosciences reports FY25 EPS ($12.52)

Artelo Biosciences (ARTL) provided a business update and announced its financial and operational results for the fiscal year...

11d ago

ARTL

Artelo Biosciences Secures Flexible Multiyear Equity Financing

Artelo Biosciences ( ($ARTL) ) just unveiled an update. On January 30, 2026, Artelo Biosciences, Inc. entered into...

30d ago

ARTL

Artelo Biosciences Granted Nasdaq Extension to Regain Compliance

Artelo Biosciences ( ($ARTL) ) has shared an announcement. On February 2, 2026, Artelo Biosciences said it received...

1M ago

ARTL

Artelo Biosciences Shareholders Back Board, Pay and Auditor

Artelo Biosciences ( ($ARTL) ) has shared an announcement. On January 30, 2026, Artelo Biosciences reconvened its previously...

1M ago

ARTL

Artelo Biosciences faces new Nasdaq compliance challenges

Artelo Biosciences ( ($ARTL) ) just unveiled an announcement. Artelo Biosciences convened but then adjourned its 2025 annual...

2M ago

ARTL

Artelo Biosciences Adjourns and Reschedules 2025 Annual Meeting

Artelo Biosciences ( ($ARTL) ) has provided an announcement. On December 31, 2025, Artelo Biosciences, Inc. convened but...

2M ago

ARTL

Artelo comments on White House Executive Order expanding CBD research

Artelo Biosciences (ARTL) commented on the White House’s recent Executive Order establishing a Medicare pilot program to support...

2M ago

ARTL

Artelo Biosciences announces publication of research on SBFI103

Artelo Biosciences (ARTL) announced the publication of new peer-reviewed research from the laboratory of Dr. Steven Laviolette, Professor...

3M ago

ARTL

Artelo Biosciences Appeals Nasdaq Delisting Decision

The latest announcement is out from Artelo Biosciences ( ($ARTL) ). On November 19, 2025, Artelo Biosciences received...

3M ago

ARTL

Artelo Biosciences downgraded to Hold from Buy at Maxim

Maxim analyst Jason McCarthy downgraded Artelo Biosciences (ARTL) to Hold from Buy. Published first on TheFly – the...

4M ago

ARTL

Artelo Biosciences Reports Increased Losses Amid R&D Investments

Artelo Biosciences ( ($ARTL) ) has released its Q3 earnings. Here is a breakdown of the information Artelo...

4M ago

ARTL

Artelo Biosciences files to sell 899,972 shares of common stock for holders

16:57 EST Artelo Biosciences (ARTL) files to sell 899,972 shares of common stock for holders Published first on...

4M ago

ARTL

Artelo Biosciences Revises Bylaws, Alters Governance Structure

Artelo Biosciences ( ($ARTL) ) has issued an announcement. On November 10, 2025, Artelo Biosciences, Inc. announced changes...

4M ago

ARTL

ARTL FAQ

What was Artelo Biosciences Inc’s price range in the past 12 months?

Artelo Biosciences Inc lowest stock price was $1.05 and its highest was $28.60 in the past 12 months.

What is Artelo Biosciences Inc’s market cap?

Artelo Biosciences Inc’s market cap is $2.49M.

When is Artelo Biosciences Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Artelo Biosciences Inc’s earnings last quarter?

Currently, no data Available

Is Artelo Biosciences Inc overvalued?

According to Wall Street analysts Artelo Biosciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Artelo Biosciences Inc pay dividends?

Artelo Biosciences Inc does not currently pay dividends.

What is Artelo Biosciences Inc’s EPS estimate?

Artelo Biosciences Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Artelo Biosciences Inc have?

Artelo Biosciences Inc has 2,124,772 shares outstanding.

What happened to Artelo Biosciences Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Artelo Biosciences Inc?

Currently, no hedge funds are holding shares in ARTL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Artelo Biosciences Inc

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.